Shares of SurModics Inc. (NASDAQ:SRDX) reached a new 52-week high during trading on Monday . The company traded as high as $29.94 and last traded at $29.53, with a volume of 29,215 shares traded. The stock had previously closed at $29.04.

A number of analysts recently commented on the company. Zacks Investment Research cut SurModics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 5th. Barrington Research raised their price target on SurModics from $27.00 to $30.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 3rd. Finally, TheStreet raised SurModics from a “hold” rating to a “buy” rating in a research note on Tuesday, April 26th.

The firm has a market cap of $385.87 million and a PE ratio of 44.22. The stock has a 50 day moving average price of $26.54 and a 200 day moving average price of $22.28.

SurModics (NASDAQ:SRDX) last issued its earnings results on Thursday, July 28th. The company reported $0.37 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.25. The company earned $19.97 million during the quarter, compared to analyst estimates of $16.31 million. During the same period in the previous year, the company posted $0.30 earnings per share. The company’s quarterly revenue was up 25.6% on a year-over-year basis. On average, equities research analysts predict that SurModics Inc. will post $1.04 earnings per share for the current year.

In related news, Director Susan E. Knight sold 1,548 shares of the firm’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $28.64, for a total transaction of $44,334.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Charles W. Olson sold 12,500 shares of the firm’s stock in a transaction on Monday, August 1st. The shares were sold at an average price of $27.08, for a total value of $338,500.00. Following the sale, the vice president now directly owns 35,531 shares of the company’s stock, valued at $962,179.48. The disclosure for this sale can be found here.

SurModics, Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company is focused on to transform its medical device business from being a provider of coating technologies to offering whole product solutions to medical device customers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.